Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00490009 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of Bexxar in Relapsed/Refractory DLCL
A Phase 2 study of Lymphoma, sponsored by Susan Knox.
- Completed
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
- 1
- Study location
NCT00490009: Completed Phase 2 study of Lymphoma, sponsored by Susan Knox.
NCT00490009 is a Phase 2 study of Lymphoma that has completed, run by Susan Knox. The registered enrollment target is 9 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00490009, a Phase 2 study of Lymphoma, has completed, sponsored by Susan Knox.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to obtain safety and efficacy data using Bexxar in patients with relapsed/refractory diffuse large cell Non-Hodgkin's lymphoma (DLCL).
Primary Outcome
Clinical response rate for all participants, reported as the sum of the numbers of patients achieving complete response (CR, complete disappearance of all lesions); functional CR (fCR, minimal residual disease but clear of disease by positron emission tomography (PET)-scan); or partial response (PR, ≥ decrease in size of lesions and negative for active disease by PET-scan). Progressive disease (PD, advancing cancer) or stable disease (not CR, fCR, or PD) not included as Clinical Response.
Conditions Studied
Interventions
- DRUG Acetaminophen
- DRUG Diphenhydramine
- DRUG Bexxar
- DRUG Potassium Iodide (KI)
Study Locations (1)
California
- Stanford University School of Medicine - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2004-09 |
| Est. Completion | 2013-06 |
| Phase | Phase 2 |
What the finished NCT00490009 record still lists
NCT00490009 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Lymphoma appearing as the primary indexed condition, and to 4 interventions - of which Acetaminophen is the first listed.
NCT00490009 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00490009 about?
NCT00490009 is a clinical study titled "Phase 2 Study of Bexxar in Relapsed/Refractory DLCL". The purpose of this study is to obtain safety and efficacy data using Bexxar in patients with relapsed/refractory diffuse large cell Non-Hodgkin's lymphoma (DLCL).
What is the current status of trial NCT00490009?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2004-09. Estimated completion is 2013-06.
What conditions does trial NCT00490009 study?
This clinical trial studies the following conditions: Lymphoma.
What interventions are being tested in trial NCT00490009?
The interventions under investigation include: Acetaminophen (DRUG), Diphenhydramine (DRUG), Bexxar (DRUG), Potassium Iodide (KI) (DRUG).
Who is sponsoring clinical trial NCT00490009?
This trial is sponsored by Susan Knox, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00490009 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00490009's enrollment target sits among peer trials
9 281st of 299 higher than 18 of 299 other Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
RECRUITING · Phase 2
-
Odronextamab in Low Tumor Volume Advanced FL
RECRUITING · Phase 2
-
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
RECRUITING · Phase 2
-
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
RECRUITING · Phase 2
-
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia